Consultative Total Parenteral Nutrition Teams: The Effect on the Incidence of Total Parenteral Nutrition‐Related Complications by Dalton, Michael J. et al.
146
Consultative Total Parenteral Nutrition Teams: The Effect on the
Incidence of Total Parenteral Nutrition-Related Complications
MICHAEL J. DALTON, PHARM.D.,* GREG SCHEPERS, R.PH., &dagger; JOSEPH P. GEE, PHARM.D., &Dagger;
CARY C. ALBERTS, PHARM.D., &sect; FREDERICK E. ECKHAUSER, M.D., &par; AND
DUANE M. KIRKING, PHARM.D., PH.D. &para;
From the University of North Carolina and Burroughs Wellcome Co., Research Triangle Park, North Carolina; Veterans Administration Medical
Center, School of Pharmacy and School of Public Health, University of Michigan, Ann Arbor, Michigan
Reprint requests to: Michael J. Dalton, Pharm.D., Clinical Research
Fellow, Burroughs Wellcome Company, 3030 Cornwallis Road, Re-
search Triangle Park, NC 27709.
* Clinical Research Fellow, University of North Carolina and Bur-
roughs Wellcome Co, Research Triangle Park, NC 27709.
&dagger; TPN Team Coordinator, Veterans Administration Medical Cen-
ter, Ann Arbor, MI.
&Dagger; Assistant Professor of Pharmacy, School of Pharmacy, University
of Michigan, Ann Arbor, MI.
&sect; Clinical Coordinator, Veterans Administration Medical Center,
Ann Arbor, MI.
&par; Chief of Surgery, Veterans Administration Medical Center, Ann
Arbor. MI.
 Assistant Professor of Pharmacy, School of Pharmacy and Assist-
ant Professor of Medical Care Organization, School of Public Health,
University of Michigan, Ann Arbor, MI.
ABSTRACT. A two part, prospective study was undertaken
to establish the existing frequency of total parenteral nutrition-
(TPN) related mechanical, metabolic, and septic complications
in an institution with a consultative TPN team (group A) and
to determine if increasing the involvement of the TPN team in
patient monitoring and verifying adherence to TPN infection
control guidelines would reduce the incidence of these compli-
cations (group B). The initial 28 consecutive patients were
managed entirely by their primary physicians with the role of
the TPN team limited to consultative activities while the next
29 patients receiving TPN were managed jointly by their pri-
mary physicians and the TPN team. Analysis of the results
show group B to have a significant reduction in metabolic
complications, decreased incidence of mechanical abnormali-
ties, and approximately equal incidences of documented sepsis.
However, when compared to the results of an institution in
which the TPN team has complete control of TPN therapy,
even the group B patients had a relatively excessive number of
TPN-related complications especially in the categories of me-
chanical and metabolic abnormalities. Thus, consultative TPN
teams do not necessarily ensure optimum TPN therapy and
institutions using this approach to provide nutrition parenter-
ally must be prepared to establish the incidence of TPN-related
complications and to expand the involvement of the TPN team
as required to control the frequency of these anomalies. (Jour-
nal of Parenteral and Enteral Nutrition 8:146-152, 1984)
The initial enthusiasm for the use of total parenteral
nutrition (TPN) therapy has been tempered somewhat
by isolated reports 1-8 and multicenter surveys9° lo suggest-
ing a high incidence of therapy-related complications.
These complications can be classified as mechanical,
metabolic, or septic abnormalities. Kaminski and Stolar’
reported a mechanical complication rate of 12.1% and
more recently Nehmell noted a much higher incidence
of 33.5%. Kaminski and Stolar’ also reported a 36.7%
occurrence of electrolyte imbalances and a 27.4% inci-
dence of significant glycosuria. They identified inade-
quate patient monitoring as the primary cause of these
complications. With regard to catheter sepsis, infection
rates as high as 42% have been reported.’ However, by
adhering to strict infection control guidelines, Ryan et
al 12 were able to reduce the rate of catheter sepsis from
20 to 3%.
To minimize the occurrence of TPN-related compli-
cations, the development of multidisciplinary teams to
manage TPN therapy has been advocated.1,10-17 As a
result many institutions have developed TPN teams to
assume primary responsibility for managing all patients
receiving TPN therapy. Studies evaluating these teams
have demonstrated substantial therapeutic and economic
benefits.1, 10-12, 17 Recently, two groups of patients receiv-
ing TPN therapy were compared prospectively with one
group managed solely by a nutrition team and the other
by private physicians without input from the TPN team.
The incidence of mechanical, metabolic, and septic com-
plications was significantly greater in the group not
managed by the nutrition team.&dquo;
Another approach to the team concept has been the
development of consultative TPN teams which allow
utilization of already available manpower and financial
resources. Most of the literature concerning consultative
teams has been descriptive reports or studies looking
only at the value of these teams in reducing septic
complications.14-16,18,19 Although Hickey et all9 showed
an overall reduction in metabolic and infectious problems
after the initiation of a consultation service, they advised
caution in interpreting their results because of a small
patient population. Thus, the value of consultative TPN
teams in minimizing mechanical, metabolic, and septic
complications has yet to be firmly established by well
controlled studies with adequate patient populations.
The Ann Arbor Veterans Administration Medical Cen-
ter (AAVAMC), a general medical and surgical teaching
hospital affiliated with the University of Michigan, es-
tablished a consultative TPN team in the fall of 1979.
Team members include a physician, several pharmacists,
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a nurse, and a dietitian. The consultative nature of the
AAVAMC TPN team dictates that ultimate responsibil-
ity for all decisions relating to TPN therapy rests with
the patients’ primary physicians and that the usefulness
of the TPN team is limited by its degree of acceptance
and utilization by the primary physicians. At the
AAVAMC, the primary physicians are usually interns
and residents that rotate to the hospital as part of their
educational experience and who vary greatly in their
knowledge of TPN therapy.
Because of the lack of documentation on the effective-
ness of purely consultative TPN teams in minimizing
complications, this prospective study was undertaken to
evaluate certain important aspects of the quality of TPN
therapy at the AAVAMC. In addition, this study facili-
tated investigating the effect of some practical modifi-
cations of a consultative approach to managing TPN
therapy on the incidence of TPN related complications.
The specific objectives of this study were:
(1) To establish the existing frequency of TPN related
mechanical, metabolic, and septic complications at the
AAVAMC.
(2) To determine if increasing the involvement of the
AAVAMC’s TPN team in patient monitoring and in
verifying adherence to TPN infection control guidelines
would significantly increase both the level of compliance
with TPN patient monitoring policies and the degree of
compliance with TPN infection control guidelines over
that observed with the existing system.
(3) To determine if increasing the involvement of the
AAVAMC’s TPN team in patient monitoring and veri-
fying adherence to TPN infection control guidelines
would significantly reduce the frequency of TPN related
mechanical, metabolic, and septic abnormalities com-
pared to the existing incidence of these complications.
METHODS
Patient Selection and TPN Team Activities
AAVAMC patients requiring TPN during a 9-month
period from June 15, 1981 to March 1,1982 were included
in this prospective study. The initial 28 consecutive
patients were managed according to existing procedures
at the AAVAMC (group A). Thus, the primary physicians
for these patients were responsible for all decisions re-
lating to TPN therapy. After a 2-wk between groups
washout period, the next 29 consecutive patients receiv-
ing TPN therapy were managed jointly by their primary
physicians and the TPN team (group B). In addition to
their usual consultative activities, the TPN team also
assumed responsibility for the following functions:
(1) Before the initiation of therapy, the TPN team
reviewed each patient’s medical record to determine the
indication for parenteral nutrition and performed base-
line anthropometric measurements. In situations where
the patients were not considered to be candidates for
TPN therapy, the primary physicians were contacted
and alternative therapy recommended. The final decision
whether or not to initiate TPN was left up to the primarv
physicians; however, in some cases the TPN team re-
quested other individuals such as the Senior Medical
Resident, the Chief of Medicine, or the Chief of Surgery
to review questionable decisions.
(2) The TPN team versified that selected observable
infection control guidelines had been followed during the
catheter insertion process and that central catheter
placement was confirmed by a chest x-ray. In cases where
violations of these guidelines were noted, TPN therapy
was withheld until corrective action had been taken or
until approval for the initiation of therapy was obtained
from the Chairman of the TPN team.
(3) The TPN team assumed responsibility for ensuring
that all laboratory tests and other TPN patient monitor-
ing parameters were obtained. This was accomplished by
placing a standardized physicians’ order form into the
patient’s medical record containing nursing orders and
laboratory testing procedures to be followed while the
patient was on TPN therapy unless otherwise specified.
(4) The TPN team continued to verify on a daily basis
that TPN infection control guidelines such as daily
dressing and tubing changes, use of an infusion device,
and the proper use of the TPN line were being followed.
Violations of these guidelines were reported to the ap-
propriate responsible individuals.
Other aspects of TPN therapy such as selection and
daily ordering of the TPN solution continued to be the
responsibility of the patient’s primary physician.
Data Collection- TPN- Related Complications
Data for both groups of patients were collected by the
primary investigators via daily monitoring of patients
medical records and attending weekly TPN teams
rounds. Only the Chairman of the TPN team and the
Clinical Pharmacy Coordinator were aware of the details
of this study or of the activities of the primary investi-
gators.
Mechanical complications were defined as technical
complications of subclavian vein catheterization.9.11 Any
structure in the upper chest or root of the neck injured
secondary to catheterization as well as other catheter
related complications such as air embolism and catheter
malposition were recorded.
Metabolic complications included abnormalities in
electrolyte status, pH, glucose, and vitamin K. Electro-
lyte, pH, and blood glucose abnormalities were defined
as serum levels beyond the normal physiological range
occurring during TPN therapy and not corrected with 24
hr.&dquo; Complications of glucosuria were defined as urine
sugar levels of 3+ or 4+, using a glucose oxidase method
(Testape), for one or more days.9 An exception to the 24-
hr correction period was inorganic phosphate in which
case a complication was defined as any level outside the
normal physiologic range occurring aft.er the initiation
of therapy. Additionally, any incidence of an increased
prothrombin time outside the normal physiologic range
developing during TPN therapy and responding to vita-
min K was classified as a complication.
A septic complication was defined as an episode of
sepsis where no other anatomic locus for this infection
could be identified other than the TPN catheter and
which resolved upon removal of the catheter. 12 Confir-
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mation of sepsis required a positive blood culture or an
infected catheter tip.
Data Collection-TPN Patient Monitoring Parameters
The level of compliance with TPN patient monitoring
policies was determined by measuring the frequency with
which laboratory tests and other patient monitoring pa-
rameters were ordered and obtained and then comparing
the results to the monitoring standards for the three
stages of TPN therapy .1,18,20,21 The baseline stage was
defined as the 7-day period immediately prior to the
initiation of therapy. The stabilization stage refers to the
first 7 days of therapy. The third stage of therapy, the
maintenance stage, was the period of TPN therapy after
the stabilization interval.
Data Collection-Degree of Compliance with Established
Infection Control Guidelines
The degree of compliance with established infection
control policies for each group was determined by mon-
itoring for violations of the more observable of these
procedures. Included were all incidences of noncompli-
ance with the following guidelines:
(1) Central venous catheter insertion should be ef-
fected away from the patient care area (use treatment
room).
(2) Sterile technique should be used during central
venous catheter insertion (gown, cap, gloves, and mask
to be worn).
(3) Proper positioning of the central venous catheter
after insertion should be established with a chest x-ray
prior to initiating therapy.
(4) A continuous infusion pump should be used to
control the administration rate of TPN fluid (patients
receiving peripheral TPN should have infusion pumps
controlling both the amino acid-glucose mixture and the
fat emulsion).
(5) In patients receiving peripheral TPN, the amino
acid-glucose mixture and the fat emulsion should be
administered simultaneously.
(6) TPN dressings should be changed every 24 hr.
(7) TPN tubing should be changed at least every 24
hr.
(8) The line through which the TPN fluid is being
administered should not be used for other purposes such
as measuring central venous pressure, administering
blood products, or the infusion of other medications.
Statistical Analysis
Student’s t-test was used to evaluate differences in age,
pretreatment percentage of ideal body weight, duration
of therapy, number of metabolic complications per pa-
tient, number of metabolic complications per patient
among those patients having a complication, number of
metabolic complications per patient per treatment day,
and the number of metabolic complications per patient
per treatment day among those patients having a com-
plication. An appropriate t-test was used to correct for
unequal variances when they occurred. The X2 test was
used to evaluate differences in the percent of patients
treated by medical versus surgical physicians, peripheral
versus central TPN, treatment location within the hos-
pital, level of compliance with patient monitoring guide-
lines, the number of central catheters pulled without
documentation of sepsis, and the number of patients in
which a metabolic complication was observed. The dif-
ference in the number of deaths during TPN therapy
was evaluated using Fisher’s exact test.
RESULTS
The incidence of TPN-related complications, the level
of compliance with TPN patient monitoring policies, and
the degree of adherence to TPN infection control guide-
lines were determined for each group. Improvement was
demonstrated in each of these categories for the group B
patients although this difference was not always statis-
tically significant.
Treatment Groups
Upon initiating this study, the first 28 patients treated
with TPN therapy were designated group A. Twenty-
nine of the next 32 patients referred for TPN therapy
were designated group B. Three patients were not treated
with TPN therapy because of team recommendations to
use an alternative method to provide nutrition. In addi-
tion, TPN therapy for three other group B patients was
discontinued early because of TPN team recommenda-
tions. These patients either no longer required parenteral
nutrition to maintain their nutritional status or were
considered terminal. No significant differences were
found between the groups except in the percent days
central versus peripheral TPN (Table I) and each group
had a similar distribution of diagnoses (Table II).
Mechanical Complications
The number of catheters placed and their resulting
mechanical complications are shown in Table III. The
most serious problems were the cases of air embolism
occurring in three group A patients when the adminis-
tration tubing inadvertently disconnected from the cen-
tral catheter. One of these patients required transporta-
tion to another hospital in order to be placed in a
hyperbaric chamber. All other patients recovered without
further complications. Overall, 35% of the patients in
group A experienced a mechanical complication com-
pared to 11% in group B. This difference was marginally
significant (p < 0.1).
Metabolic Complications
A detailed comparison of the observed occurrence of
metabolic imbalances is included in Table IV. The treat-
ment groups were examined for differences in the per-
centage of patients who had an abnormality, number of
episodes per patient, number of episodes per patient
among those patients having a complication, the numbei
of episodes per patient per treatment day, and the num-
ber of episodes per patient per treatment day amon~
those patients having a complication. The imbalance rat(




° X2 and t-test, no significant difference except % days central TPN
(p < 0.005).





the number of bicarbonate abnormalities per patient per
treatment day among those patients having a bicarbon-
ate abnormality, and the number of prothrombin time
imbalances per patient among those patients having a
prothrombin time abnormality. None of the situations
i when the complication rate was greater for group B was
I statistically significant whereas the decreases in compli-
! cations observed for group B patients were frequently
t statistically significant. Evidence for an overall trendtoward more favorable results in group B patients is
suggested by the highly significant differences in the
mean number of episodes per patient (p < 0.0005), the
mean number of episodes per patient among those pa-
tients having a complication ( p < 0.025), and the total
number of episodes per patient per treatment day ( p <
0.005) (Table IV). Magnesium was not included in the
data analysis because less than 50% of the patients in
group A had any levels drawn.
Septic Complications
Both treatment groups had one episode of documented
catheter sepsis (Table V). The group B patient subse-
quently developed systemic candidiasis requiring long-
term treatment with Amphotericin B before clearing.
Also recorded for each group was the number of catheters
that were pulled because of suspected sepsis but without
subsequent documentation of sepsis. This occurred on
nine occasions in group A us two in group B (p < 0.05).
Patient Monitoring
The level of compliance with TPN patients monitoring
policies as contained in the AAVAMC TPN team pro-
tocol was determined for each group (Table VI). These
tests were classified as being either a nutritional, meta-
bolic, or miscellaneous patient monitoring parameter, as
well as being divided into baseline, stabilization, and
maintenance monitoring periods. It should be noted that
no attempt was made to weight the tests by the frequen-
cies at which they were supposed to be obtained. During
both the stabilization and maintenance periods, the pa-
tients in group B had highly significant increases in the
level of patient monitoring compared to group A (p <
0.0005). Although Group B patient monitoring was also
improved during the baseline period, the difference was
not statistically significant.
Adherence to Infection Control Guidelines
Table VII shows the degree of adherence to infection
control guidelines. Overall, the results were very similar
for each group except in utilizing sterile technique during
the catheter insertion procedure. Failure to wear caps,
gowns, or mask when inserting the catheter was the most
common violation. The low percentage of patients who
had catheters inserted away from the treatment area,
20% for group A compared to 25% in group B, reflects a
hospital decision not to enforce this policy. Other than
using an infusion pump with fat emulsion during periph-
eral TPN, adherence to other infection control guidelines
was greater than 90% for each group and, therefore,




The results from group A reflect the existing level of
TPN related complications in an institution with a con-
sultative TPN team. Thus, an evaluation of this data
will provide insight into the value of this type of team in
minimizing these abnormalities. However, it should be
noted that because reports describing complication rates
during TPN therapy rarely use exactly the same criteria
when defining an abnormality, discrepancies in compli-
cation rates do not necessarily indicate real differences
in results.




° ABN, abnormality; I, % of patients with complication; II, no. of abnormal episodes per patient; III, no. of episodes per patient among those
patients having an abnormality; IV, no. of abnormal episodes per patient per treatment day; V, no. of episodes per patient per treatment day
among those patients having an abnormality; BG, blood glucose; UG, urine glucose; PT, prothrombin time; T, mean no. of complication in that
category.
b p < 0.05.
c p < 0.005.




Percentage compliance with monitoring standards’
° Nutritional tests include weight, complete blood count, Fe/total
iron binding capacity, UUN, and creatinine. Metabolic tests include
electrolytes, SMA12, Mg++, and PT/PTT. Miscellaneous tests include
vital signs and urine glucose. SMA~2 contains total protein, albumin,
Ca++, phosphate, blood urea nitrogen, creatinine, bilirubin, uric acid,
cholesterol, glucose, SGOT, and alkaline phosphatase.
b p ~ 0.0005.
TABLE VII
Adherence to infection control guidelines
group A compares poorly with results reported by most
institutions.’, 9,&dquo;,’9 Nehmell reported mechanical compli-
cation rates of 3 and 33% in treatment groups managed
with and without TPN team control, respectively. Com-
plication rates of less than 3% are currently being pub-
lished with increasing frequency when adequate knowl-
edge and control of the proper techniques for insertion
and care of central venous catheters are present.8 Most
of the abnormalities in the present study occurred as a
direct result of tubing disconnections at either the cath-
eter hub or a junction in the administration set. This
suggests inadequate catheter/tubing care after the inser-
tion process as does the dislodging of the jugular catheter.
As a result of TPN team intervention, Luer loc tubing is
now being used in all central catheters as well as contin-
uing to tape all tubing junction sites. Both of the mal-
positioned catheters were noted on chest x-ray before
initiating therapy and were repositioned without further
difficulty.
The incidence of metabolic complications for group A
also does not compare favorably with studies from other
institutions with or without TPN teams.8,9,11,19 An aver-
age of 58.3% of the patients had at least one abnormality
in each of the categories evaluated. Plus, each patient
had an average of 2.2 comlications for each metabolic
category while on TPN therapy. Kaminski and Stolar9
reported that with minimal TPN team involvement,
36.7% of the patients had electrolyte imbalances while
in Nehme’s study,&dquo; 54.8% of the patients controlled by
private physicians had metabolic complications com-
pared to 5% of those managed by the TPN team. Nehme
allowed a 48-hr correction period for electrolytes com-
pared to a 24-hr limit in the present study whereas in
the report by Kaminski and Stolar, the correction time
was either the same or shorter than the present study.
Further examination of the metabolic complication re-
sults reveals fairly universally inadequate anticipation of
requirements and failure to correct abnormalities rapidly
once they occurred both of which are probably related to
a low level of patient monitoring and less than optimal
understanding of electrolyte requirements in TPN pa-
tients. A purely consultative TPN team does not appear
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to necessarily allow good control of metabolic complica- <
tions. ,
The 5% infection rate in group A attributable to cath-
eter sepsis, as defined by Ryan et al, 12 is within the range
reported by investigators when adhering to good sterile
technique during catheter insertion and subsequent
care.2~s~12 There was, however, a seemingly large number
of catheters pulled because of suspected sepsis but with-
out subsequent documentation. Several of these patients
improved without identifying a source of infection.
Second Objective
As evidenced by Table VI, the increased involvement
of the TPN team significantly improved the level of
patient monitoring. Even more improvements would
have been found except that laboratory tests ordered on
weekends were frequently not done. The relatively poor
level of patient monitoring during the baseline period
was due to a hesitancy by physicians to withhold TPN
therapy until baseline data could be obtained. However,
given the high level of metabolic complications in both
groups, early documentation of electrolytes and other
monitoring parameters may be necessary to reduce these
to a more acceptable frequency.
The degree of adherence to infection control guidelines
for both groups was very similar. The biggest change was
the improvement in sterile technique during catheter
placement observed in group B. The primary physicians
eventually noticed both the investigators and the TPN
team were monitoring the conditions during catheter
placement and this awareness probably contributed to
the increased compliance with sterile technique guide-
lines. Neither of the groups routinely used infusion de-
vices to administer peripheral fat emulsion reportedly
because of an equipment shortage. Although patients
were not specifically monitored for the incidence of phle-
bitis during peripheral TPN, the rate of occurrence of
this abnormality seemed to be fairly high and may have
been related to fat emulsion administration techniques.
Third Objective
The third objective was to determine if an increased
involvement of the TPN team would decrease TPN
complications. Analysis of the results show a significant
reduction in metabolic complications, decreased inci-
dence of mechanical abnormalities, and approximately
equal incidences of documented sepsis but reduced num-
bers of suspected sepsis without documentation.
Although patients in group B tended to have fewer
metabolic imbalances in all categories evaluated, the
reduction was most significant for the percentage of
patients with a complication, the number of episodes per
patient, the number of episodes per patient among those
patients with a complication, and the number of episodes
per patient per treatment day. In order to determine how
quickly an abnormality was corrected once it occurred,
patients were evaluated in categories III and V (Table
IV). The patients in group B generally did better in both
areas but the differences were usually not statistically
significant. Despite the improvement seen in group B,
these patients still had an average abnormality rate for
each category of 26.3 ~. Perhaps more involvement by
the TPN team in other aspects of therapy such as stand-
ardization of TPN solutions or writing TPN solution
orders would help improve metabolic control.
The relatively large number of mechanical problems
in group A, especially air embolisms, was probably coin-
cidental since there is no evidence suggesting that air
embolism had been a problem in the past at the
AAVAMC. The increased daily monitoring by the TPN
team and the equipment change to Luer loc connectors
helped prevent problems in group B patients and should
minimize reoccurrence in the future. Probably the best
method for a TPN team to have an impact on mechanical
complications other than those related to catheter care
would be to assume responsibility for catheter placement.
The number of problems associated with catheter place-
ment has been shown to be related to the experience of
the individual performing the procedure (8).
Changes in the TPN team had no definite effect on
the incidence of catheter sepsis. However, the low level
of compliance with all the recommendations for sterile
technique observed in group A patients along with the
number of catheters pulled because of suspected catheter
sepsis causes some concern. Catheters were either being
changed needlessly or possibly undocumented catheter
sepsis was present. Mechanisms to ensure compliance
with all sterile technique recommendations should be
considered.
CONCLUSION
The existing frequency of TPN related complications
at the AAVAMC (group A), reflecting the influence of a
purely consultative TPN team, is greater than the re-
duced level of these abnormalities possible when TPN
teams have more control of therapy. Modification of the
TPN team (group B) resulted in increased patient mon-
itoring and adherence to infection control guidelines as
well as decreased mechanical and metabolic complica-
tions. However, the incidence of these abnormalities
remained relatively excessive. Therefore, additional re-
sponsibilities and activities for the TPN team should be
considered in order to further reduce TPN related com-
plications and improve therapy.
ACKNOWLEDGMENTS
The authors acknowledge Nabil Khalidi, Pharm.D.,
coordinator of the University of Michigan Hospital Par-
enteral-Enteral Nutrition Team, for his valuable input
concerning the design and conduct of this study. We also
thank Baxter-Travenol Company for their support via a
grant to the Ann Arbor VA Hospital to help develop a
TPN team.
REFERENCES
1. Thomas RJ: The organization, methods, and experience of a par-
enteral nutrition service. Aust NZ J Surg 48:539-544, 1978
2. Goldman DA. Maki DG: Infection control in total parenteral
nutrition. JAMA 223:1360-1634, 1973
152
3. Maki DG, Goldmann DA, Rhame FS: Infection control in intra-
venous therapy. Ann Intern Med 79:857-887, 1973
4. Freeman JB, Lemire A, MacLean LD: Intravenous alimentation
and septicemia. Surg Gynecol Obstet 135:708-712, 1972
5. Copeland EM III, MacFayden BV Jr, McGown C, et al: The use of
hyperalimentation in patients with potential sepsis. Surg Gynecol
Obstet 138:377-380, 1974
6. Bently DE, Lepper MH: Septicemia related to indwelling venous
catheters. JAMA 206:1749-1752, 1968
7. Dudrick SJ, MacFayden BV Jr, Van Buren CT, et al: Parenteral
hyperalimentation problems and solutions. Ann Surg 176:259-264,
1972
8. Vazquez RM: Modern clinical nutrition&mdash;part 6: subclavian cath-
erization. Am J Intravenous Ther Clin Nutr 7:11-29, 1980
9. Kaminski MV, Stolar MH: Parenteral hyperalimentation&mdash;a qual-
ity of care survey and review. Am J Hosp Pharm 31:228-235, 1974
10. Infection control in hyperalimentation therapy, Hospital Infections
and Microbiological Control Branches, Bacterial Disease Division,
Bureaus of Epidemiology. Center for Disease Control: Atlanta, GA,
1972
11. Nehme AE: Nutritional support of the hospitalized patient: the
team concept. JAMA 243:1906-1908, 1980
12. Ryan JA, Abel RM, Abbott WM, et al: Catheter complications in
total parenteral nutrition. N Engl J Med 390:757-760, 1980
13. Blackburn GL, Bristrian BR, Maini BS, et al: Nutritional and
metabolic assessment of the hospitalized patient. JPEN 1:11-22,
1977
14. Skoutakis VA, Martinez DR, Miller WA, et al: Team approach to
total parenteral nutrition. Am J Hosp Pharm 32:693-697, 1975
15. Mutchie KD, Smith KA, MacKay MW, et al: Pharmacist monitor-
ing of parenteral nutrition: clinical and cost effectiveness. Am J
Hosp Pharm 36:785-787, 1979
16. Powell-Tuck J, Farwell JA, Nielsen T: Team approach to long-
term intravenous feeding in patients with gastrointestinal disor-
ders. Lancet 2:825-828, 1978
17. Greenlaw CW: Pharmacist as team leader for total parenteral
nutrition therapy. Am J Hosp Pharm 36:648-650, 1979
18. Swenson JP, Edwards D, Chamberlain M, et al: A total parenteral
nutrition protocol. Drug Intell Clin Pharm 1:714-720, 1977
19. Hickey MM, Munger TO, Salen RB, et al: Parenteral nutrition
utilization: evaluation of an educational protocol and consult serv-
ice. JPEN 3:433-437, 1979
20. Koda-Kimble MA, Katcher BS, Young LY, et al (eds.): Applied
therapeutics for clinical pharmacists, 2nd ed. Applied Therapeutics
Inc, San Francisco, 1978, pp 57-70
21. Eriksson B, Douglass HO: Intravenous hyperalimentation: an ad-
junct to treatment of malignent disease of upper gastrointestinal
tract. JAMA 243:2049-2052, 1980
